Navigation Links
VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided a financial and operational update since the filing of its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 14, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

VaxGen had approximately $59 million in cash and equivalents and investment securities as of June 30th, 2008, or $29 million net of the Company's $30 million of outstanding convertible debt. VaxGen reported a net loss for the second quarter of $10.4 million, reflecting a non-cash asset impairment charge of $8.5 million associated with the carrying value of the Company's manufacturing and laboratory assets. VaxGen's management and board determined to take this charge in light of an aborted transaction to sell the facility and associated equipment, and reflecting the length of time that the facility has been marketed without success.

James P. Panek, VaxGen's President and CEO, commented "While we have taken several important steps to preserve capital, we are obviously disappointed that the anticipated sale of the manufacturing plant and equipment fell through, having completed diligence and agreed to terms, for reasons entirely unrelated to VaxGen or the plant. In light of this, however, our expectations going forward need to reflect the difficulty we have experienced selling this asset. The encumbrance of the facility lease represents our single largest remaining financial liability."

Since the end of the second quarter, the Company has spent $18.3 million repurchasing $22 million in face value of its convertible debt, and received repayment of $6.3 million from Raven biotechnologies in respect of the bridge loan and accrued interest. As a result, VaxGen had approximately $46.5 million in cas
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
2. VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven
3. VaxGen Restructures Following Termination of Proposed Merger
4. Study provides hope that some transplant patients could live free of antirejection drugs
5. Study provides hope that some transplant patients could live free of anti-rejection drugs
6. USAID Provides Additional Wildfire Assistance to Greece
7. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
8. New knock-out gene model provides molecular clues to breast cancer
9. PreMD Provides Update on 510(k) Application for PREVU(x) POC
10. SIV infection of natural hosts provides new insights into HIV disease complexity
11. Microarray provides 3 genomic guides to breast cancer treatment decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Finding may lead to new therapies for preterm labo...- Researchers say they,ve found the switch that ac... childbirth, a finding that may lead to therapies ... normally binds the protein IP on the surface of t... inactive during pregnancy. , But researchers ...
(Date:11/21/2008)...Special meeting of shareholders to be held on Janu...e-FirstCall/ - Med-Emerg International Inc. ("MedE...iders of health services, announced today that it ...erior Court of Justice concerning its previously a...ursuant to which AIM Health Group Inc. ("AIM") wil...
(Date:11/21/2008)... HOUSTON(Nov. 21, 2008)The University of Texas Hea...ogram, Training Excellence in Aging Studies (TEXAS...hrough a prestigious $2 million award from the Don...tching funds., "This will allow us to teach geria... junior medical student to practicing physicians. ...
(Date:11/21/2008)...LOVELAND, Colo., Nov. 21 ...ced it will present at the New York Society of,Se... Pharma Conference on,December 2, 2008 at 1177 Av...The presentation is scheduled to begin at 9:35 a.m... be available via live webcast and for two weeks,...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...heir counterparts in the Health department of the ...g// a fast-food joint swarming with rats to contin...sible for the “shoddy audit” resigned Monday. The...d on videotape, created a national stir and prompt...
... with diabetes has another new risk- it heightens ...ou think and learn//, and may in fact set you on t... in the April issue of Archives of Neurology, one ... "Among cardiovascular risk factors, type 2 diabe...
...ed out to mark Mental Health Action Week, in Scotl...friends// who have experienced mental distress at ...at almost 90 percent of those suffering from menta...ing it to others, out of shame for appearing weak ...
... the Framingham Heart Study, dietary fat intake is...or 13 percent// of the study population with a spe...ne (APOA5), higher dietary fat was not related to ...gues analyzed several common gene variants known a...
Other Medicine News:Health News:Officials Indicted for Allowing a Fast Food Joint Teeming With Rats in New York to Function 2Health News:Diabetes May Bring You A Step Closer To Alzheimer’s Diseas 2Health News:Study Finds Dietary Fat Interacts With Genes 2Health News:Study Finds Dietary Fat Interacts With Genes 3
(Date:11/20/2008)...wswire/ -- The Scandinavian-based drug,developmen... studies on its,lead antimicrobial candidate LTX-...udies showed that the novel lytic peptidomimetic h...ntly better towards killing Staphylococcus,aureus...ndard drugs. In,addition to this it has proven ef...
(Date:11/19/2008)...tistical significance , , ISELIN, N.J., Nov...n (Nasdaq: PARS ) today announced results from i...sion (NE) drug delivery technology formulated with...i-center, randomized, double-blinded, placebo-cont...the Company,s 3% Diclofenac Diethanolamine NanoEmu...
(Date:11/19/2008)... Isogen, a contract development and,manufacturing... the first,phase launch of its contract facility ...ddress the process, facility and capacity problems...iched, low-volume clinical and,early-stage commer...anies can invest over $100 million and four years ...
(Date:11/18/2008)...rn more, make a donation or send a Christmas Seals...-USNewswire/ -- Millions will receive Christmas Se...an Lung Association. These decorative holiday stam...ing back to 1907 when the Lung Association led eff...mericans alive today have no vivid memories of how...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Desert Radiologists Sets Safe Practice Standards 17314 1Desert Radiologists Sets Safe Practice Standards 17314 2The Penis Diet 3A A Healthy Solution for Men Challenged by Erectile Dysfunction 17312 1The Penis Diet 3A A Healthy Solution for Men Challenged by Erectile Dysfunction 17312 2Chocolate bar shown to lower cholesterol 2976 1Chocolate bar shown to lower cholesterol 2976 2Health Plan One Closes 246 5 Million Series A Financing 17309 1Health Plan One Closes 246 5 Million Series A Financing 17309 2Health Plan One Closes 246 5 Million Series A Financing 17309 3
...linical Results Demonstrate Potential of ONCONASE ...June 27, 2007 /PRNewswire-FirstCall/ --,Alfacell C...NASE,the company,s lead drug candidate, is active...lls. , The pre-clinical in vitro and in vivo data ... 1: 107-116) through a collaboration,between Alfac...
...ORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A...h clinical and preclinical,data that support the s...f action of Defibrotide in combination with antica...esented both an update,from the Company,s ongoing ...tory or relapsed multiple myeloma with Defibrotide...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3
Zeiss offers a full range of filter sets for a variety of applications.
Dust covers for a variety of Zeiss microscopes
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark
...that offers you much more than you have ever expec...e impressed by the outstanding quality, and functi... work as easy and safe as possible thus increasin... more time for the observation. , Contrasting...
Medicine Products: